Uncategorized

No surprises, no recalls all good

Given the way things have been going this week with the Medtronic recall and the Insulet notice it’s refreshing that the Dexcom earnings announcement had no surprises. Yes as Momma Kliff used to say surprises can be fun but dull isn’t so bad either. Although we wouldn’t exactly classify Dexcom’s earnings as dull as the company continues to click on all cylinders. If anything one has to wonder with their...

Slow your roll

This morning Insulet joined Medtronic issuing a correction for their OmniPod DASH system. Per a company issued press release; “As part of our ongoing quality monitoring processes, we have identified that on rare occasions, the Omnipod DASH PDM may suggest an inaccurate bolus amount based on a blood glucose value that is more than 10 minutes old when the user does not exit the bolus calculator as designed or when a...

The ship is taking on water

As if Medtronic doesn’t have enough problems with their diabetes franchise now word is spreading of, yet another insulin pump recall this one impacting over 320,000 pumps. This recall which apparently began in November of last year is related to an issue with the pump’s retainer ring. Per a notice on the company’s web site; “The MiniMed™ 600 series insulin pump is designed with a pump retainer ring to lock the...

A step closer?

Yesterday Companion Medical announced a deal with Senseonics to integrate Senseonics sensor data into the InPen system. Companion already has a deal with Dexcom, and we suspect at some point will also strike a deal with Abbott even though Abbott continues to invest in Bigfoot. In these days of interoperability with all the toys talking with all the other toys deals such as these are becoming commonplace. The goal here is...

Infrastructure Matters

This morning we read about Novo Nordisk spending over $100 to expand their manufacturing facilities in Denmark. This comes after Novo bought an existing facility in North Carolina to expand capacity here in the US. Lilly has also been on a spending spree as has Abbott and Dexcom. While this isn’t big news it does point to an often-overlooked hurdle faced by every company seeking to enter the crowded diabetes...

Who’s next?

There are just certain constants in this wacky world, one of which is never ever try and understand some of the deals that are done. As we have said many times no deal no matter how far-fetched no matter how illogical it seems at the time do not question why it’s being done as nine times out ten logic has nothing to do with it. Listen if someone is dumb...

A way out, a way in

This morning Zealand Pharma announced they were acquiring the assets of Valeritas. Per a company issued press release; “Valeritas Holdings, Inc. (NASDAQ: VLRX) ("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced an agreement to sell substantially all of the business to Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"), a Denmark-based biotechnology company. The transaction contemplates the retention of nearly the entirety...

One more step

Before we begin today a moment to acknowledge a true Hollywood icon and legend Kirk Douglas who passed at the age of 103. Perhaps best known for his role of Spartacus he was the consummate professional from an era long gone. RIP Kirk as you will be missed thankfully your great performances will live on forever. We’d also like to give a shout out to Utah Senator Mitt Romney, no matter...

Upside Down

Looking at the results released by Novo Nordisk and listening to the call anyone who’s been following this company for more than a few years must feel like the world has turned upside down. While it’s difficult to imagine today it wasn’t that long ago that insulin sales were driving Novo and GLP-1 sales were a mere afterthought. Today the exact opposite is true, now that insulin has fully commoditized...

Not as easy as it seems

Momma Kliff used to say that just because something that is difficult to achieve does not mean you shouldn’t try, just be prepared to deal with the difficulties in achieving it. As usual Mom was spot on when it comes to the quest of developing an insulin delivery system which is controlled via a patient’s smartphone. Ask any patient who uses the OmniPod from Insulet what feature they crave most...